Colorectal cancer is the fourth most common noncutaneous malignancy in the United States
and the second most frequent cause of cancer-related death. Over the past 12 years …

Peritoneal spread of tumors is a major problem in cancer management. Patients develop a
marked deterioration in quality of life and shortened survival. This is in part due to bowel …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …

Background To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS
mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line …

Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …

Background Fluoropyrimidine-based chemotherapy plus the anti–vascular endothelial
growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic …

Background Patients with poor-risk rectal cancer defined by MRI can be at high risk of
disease recurrence despite standard chemoradiotherapy and optimum surgery. We aimed to …

The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical
management, perioperative treatment, posttreatment surveillance, management of recurrent …